SCHEMBL3408719

SCHEMBL3408719

O=C(O)Cc1cccc2c1CCCC2

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRB P28702 9/20 0.55
RXRA P19793 8/20 0.55
RXRG P48443 7/20 0.55
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
AKR1B1 P15121 1/20 0.46
ALDH1A1 P00352 2/20 0.45
TDP1 Q9NUW8 1/20 0.44
TBXA2R P21731 2/20 0.44
MEN1 O00255 1/20 0.44
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8638947 0.98 RXRB (0.54) RXRBRXRARXRGBCL2L1BAD
SCHEMBL28739318 0.96 RXRB (0.55) RXRBRXRARXRGBCL2L1BAD
SCHEMBL10863869 0.84 ALDH1A1 (0.55) RXRBRXRARXRGBCL2L1BAD
SCHEMBL5659543 0.82 RXRB (0.59) RXRBRXRARXRGLMNASMN1; SMN2
SCHEMBL30150923 0.81 RXRB (0.43) RXRBRXRARXRGBCL2L1BAD
SCHEMBL19212186 0.81 RXRB (0.43) RXRBRXRARXRGBCL2L1BAD
SCHEMBL6662229 0.81 ALDH1A1 (0.51) RXRBRXRARXRGBCL2L1BAD
SCHEMBL8055673 0.78 AKR1B1 (0.45) RXRBRXRARXRGAKR1B1TDP1
SCHEMBL8486125 0.78 BCL2L1 (0.44) RXRBRXRARXRGBCL2L1BAD
SCHEMBL8481831 0.78 ALDH1A1 (0.44) RXRBRXRARXRGBCL2L1BAD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
EP-2254879-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2010-12-01 EP disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 WO disclosed
US-4898876-A Benzoylpiperazine esters and a process for their production KOWA CO., LTD. (JP) 1990-02-06 US disclosed
EP-0098713-A2 Benzoylpiperazine esters and a process for their production KOWA COMPANY, LTD. (JP) 1984-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 RXRB 328/4885RXRA 260/4885RXRG 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.